Health Hazard?

English, Joel; Klein, Rob; Niehaus, Tess; Ross, Joyce M.
December 2005
Marketing Health Services;Winter2005, Vol. 25 Issue 4, p14
Academic Journal
The article presents an exploration into the ethical aspects of healthcare marketing in reaction to the article "Advertising by Academic Medical Centers," which appeared in the March 28, 2005 issue of the "Archives of Internal Medicine." The report is criticized by the authors and it is suggested that healthcare advertising is not bound to only report along the lines of clinical-trial research. Specific aspects of the report are re-evaluated, pointing out flaws in its market research definitions, design, and analysis.


Related Articles

  • American universities operate fewer industry trials. Ready, Tinker // Nature Medicine;Feb2003, Vol. 9 Issue 2, p157 

    Reports the decline in the number of industry-sponsored trials conducted by academic health centers in the United States. Potential conflicts with industrial sponsors; Drug testing; Plans to coordinate multi-center trials.

  • Untitled. Gershon, Diane // Nature;6/21/2001, Vol. 411 Issue 6840, p6 

    Reports that the movement of clinical trials from the public to the private sector is forcing academic health centres to re-examine their role. Reason for opting to outsource the management of clinical trials to commercial entities; One of the benefits and challenges of working within a...

  • AMCs. The New, Old Thing? Henderson, Lisa // Applied Clinical Trials;Feb2009, Vol. 18 Issue 2, p12 

    The article discusses various reports published within the issue including one about the Academic Medical Center, its role in clinical trials and the changes in its drug development.

  • Physicians' Outlook on Participation. Glass, Harold E.; Glass, Jesse M. // Applied Clinical Trials;Aug2012, Vol. 21 Issue 8, p16 

    The article discusses the study which examines the investigator-related data on clinical trial sites from the Asia Pacific region. The study used questionnaires, which contain basic areas such as site description on clinical trial experience and the potential aspects of clinical trial. Results...

  • Breaking the Camel's Back: Multicenter Clinical Trials and Local Institutional Review Boards. Burman, William J.; Reves, Randall R.; Cohn, David L.; Schooley, Robert T. // Annals of Internal Medicine;01/16/2001, Vol. 134 Issue 2, p152 

    Assesses the federal regulatory actions against local institutional review boards (IRB) of academic medical centers in the United States. Responsibilities of IRB; Role of IRB in reviewing safety reports from multicenter clinical trials; Assurance of patient safety.

  • Institutional Review Boards: A Crisis in Confidence. Levine, Robert J. // Annals of Internal Medicine;01/16/2001, Vol. 134 Issue 2, p161 

    Editorial. Comments on issues facing institutional review boards (IRB) of academic medical centers in the United States. Suspension of IRB due to inadequate review of safety reports; Implication of randomized clinical trials; Lack of exploitation or injury to research subjects.

  • Academic centers vie for research dollars. Japsen, Bruce // Modern Healthcare;9/12/94, Vol. 24 Issue 37, p72 

    Reports on the competition between academic centers and drug companies for lucrative clinical-trial contracts. Changing business needs; Chicago Center for Clinical Research as one competitor to academic centers; Full hospital beds as academic centers' goal; Academic health centers' admission of...

  • SaÄŸlık eÄŸitiminin annelerin taburculuÄŸa hazır oluÅŸ, doÄŸum sonu güçlük yaÅŸama ve yaÅŸam kalitesine etkisi. ALTUNTUĞ, Kamile; EGE, Emel // Turkish Journal of Research & Development in Nursing;Aug2013, Vol. 15 Issue 2, p45 

    Objective: It was aimed in the study to determine the effects of the education, which started at the last trimester of gravidity and lasted at hospital and home postpartum, on mothers' readiness for postpartum discharge from the hospital, postpartum complaints, and quality of life. Method: An...

  • TRIALS IN ONCOLOGY ONLY GOING UP.  // Applied Clinical Trials;Jan2010, Vol. 19 Issue 1, p18 

    The article offers information about the increasing worldwide market sales in oncology drugs based on the Cutting Edge Information 2008 data in the U.S. John W. Hubard, PHD, FCP, Global President, ICON Clinical Research, said that the oncology space activity is multiplying and the new drugs that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics